Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel, Carboplatin, and Trastuzumab in HER2+ Metastatic Breast Cancer
NCT00003612Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 1999
- Primary completion
- Dec 2005
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of paclitaxel, carboplatin and trastuzumab in breast cancer (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Response Rate at 5 years. Started Apr 1999; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00003612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003612.